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Red cell Na/Li countertransport in non-insulin-dependent diabetics
with diabetic nephropathy. Genetic predisposition to essential hyperten-
sion, as indicated by increased maximal velocity of Na/Li counter-
transport in red cells, has been suggested as a marker for the risk of
developing diabetic nephropathy. To evaluate the validity of this
concept in non-insulin-dependent diabetics, we measured the maximal
velocity of Na/LP countertransport in red cells in 18 male diabetics
suffering from proteinuria due to biopsy proven diabetic glomerulo-
sclerosis (GFR: 51 [range 27 to 146] ml/min/1.73 m2), 17 male diabetics
with normoalbuminuria, and in 18 sex-, age-, and body mass index-
matched healthy control subjects. Na/Li countertransport was iden-
tical in patients with and without diabetic nephropathy, 0.43 (0.24 to
0.92) versus 0.44 (0.20 to 0.83) mmol/(liter cells x hr), but was elevated
compared to control subjects, 0.32 (0.09 to 0.73; P < 0.05). Arterial
blood pressure was elevated in patients with nephropathy (162/92
21/9 mm Hg) compared to normoalbuminuric patients (132/82 15/7)
and control subjects (133/83 14/7 mm Hg; P < 0.001). Our study does
not support the hypothesis that the risk of diabetic nephropathy in
non-insulin-dependent diabetes is associated with a genetic predisposi-
tion to hypertension. Diabetes per se seems to enhance Na/Li
countertransport activity.
In a recent cross sectional study of non-insulin-dependent
diabetic patients we found a high prevalence (14%) of macroal-
buminuria ( 300 mg/24 hr) [1]. Longitudinal studies have
revealed a cumulative incidence of proteinuria as high as 40 to
50% in non-insulin-dependent diabetic patients [2, 3]. The
susceptibility to nephropathy cannot be explained solely by
differences in metabolic control [4] suggesting that other fac-
tors, such as genetic, are involved in the pathogenesis of
diabetic nephropathy. This suggestion is supported by the
finding of a higher frequency of end-stage renal disease, attrib-
uted to diabetic nephropathy, in blacks, Hispanics, and Pima
Indians as compared to Caucasians [5—7]. Recently, Krolewski
et al [8] and Mangili et al [9] suggested that genetic predisposi-
tion to essential hypertension as indicated by elevated Na/Li
countertransport in red cells may serve as a marker for the risk
of nephropathy in insulin-dependent diabetic patients.
To evaluate the validity of the above-mentioned concept in
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non-insulin-dependent diabetic patients, we measured the max-
imal velocity of Na/Li countertransport in red cells in
patients with and without diabetic nephropathy.
Methods
Patients
In a recent cross sectional study of all (N = 363; 139 women)
non-insulin-dependent diabetic patients less than 66 years of
age attending Hvidore Hospital during 1987, we identified 50
patients (7 women) with persistent macroalbuminuria ( 300
mg/24 hr). All these patients were referred to the departments of
nephrology for further examination except six patients who did
not want further evaluation. Four patients did not attend, and
kidney biopsy could not be performed in six patients due to
contraindications. A renal biopsy was performed in the remain-
ing 34 patients (2 women). Insufficient material was obtained in
one patient. The kidney biopsies revealed diffuse and/or nodu-
lar diabetic glomerulosclerosis with no other lesions in 24
patients (all males), while the remaining nine patients (2
women) had a variety of non-diabetic glomerulopathies. All the
above-mentioned non-insulin-dependent diabetic patients suf-
fering from persistent albuminuria due to a biopsy-proven
diabetic glomerulosclerosis who were attending Hvidöre Hos-
pital in 1988 were invited to join the present study. Eighteen
males accepted the invitation to participate (Table 1). The
patients were regarded as suffering from non-insulin-dependent
diabetes mellitus if they were treated by diet alone or addition-
ally with oral hypoglycemic agents, or if they were treated with
insulin and had an onset of diabetes after the age of 40 and a
body weight in excess of the ideal body weight [10]. Lean
insulin treated patients (< 100% ideal body weight) had a
glucagon test performed, and non-insulin-dependent diabetes
was diagnosed if a stimulated C-peptide value was  0.60
pmollml [10]. Fifteen patients had arterial hypertension, that is,
 160/95 mm Hg or were on antihypertensive treatment.
Twelve of the 15 hypertensive patients received antihyperten-
sive treatment (diuretics, N = 11; selective beta-blockers, N =
7; angiotensin I converting enzyme inhibitors, N = 4; and
calcium-channel blockers, N = 1) at the time of investigation.
Persistent albuminuria was defined as urinary albumin excre-
tion  300 mg!24 hours in at least three consecutive, sterile
non-ketotic 24-hour urine samples.
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Table 1. Clinical characteristics of patients with non-insulin-dependent diabetes with and without nephropathy and in healthy non-diabetic
controls
Diabetics with
nephropathy(N = 18)
Diabetics without
nephropathy(N = 17)
Non-diabetics
(N = 18)
Age years 56 9 55 7 56 9
Known duration of diabetes years 11 7 12 5 —
Retinopathy 6/5/6 14/3/0 —
nil/simple/proliferative
Body mass index 28.0 (24.5—42.4) 26.3 (23.7—33.4) 26.5 (18.6—31,7)
kg/rn2
Treatment 1/8/9 5/5/7 —
diet/oral hypoglycemic agent/insulin
The kidney biopsies revealed diffuse (N = 14) and nodular (N
= 4) diabetic glomerulosclerosis with no other lesions. A
control group of 17 normotensive non-insulin-dependent dia-
betic patients with urinary albumin excretion rate in the normal
range ( 30 mg/24 hr, as defined on a previous consensus
conference [11]), matched for sex, age, diabetes duration,
antidiabetic treatments, and body mass index were enroled
(Table 1). Furthermore, 18 healthy age-, sex- and body mass
index-matched subjects were investigated. The experimental
design was approved by the local ethical committee, and all
subjects gave their fully informed consent.
Methods
All subjects were investigated in the out-patient clinic be-
tween 4 and 6 p.m. Actual medication, history of hypertension,
kidney disease, and cardiac disease were recorded in all sub-
jects.
Arterial blood pressure was measured in the sitting position
after 10 minutes of rest and averaged. The measurements were
carried out with an appropriately sized cuff (25 x 12 cm in lean
adults, 30 x 15 cm in obese) and an automatic, electronic device
(Takeda Medical UA-751, Tokyo, Japan) [121. Arterial hyper-
tension was defined according to the World Health Organiza-
tion's criteria ( 160/95 mm Hg) or as prescribed antihyperten-
sive treatment. Mean arterial blood pressure was calculated as
diastolic blood pressure plus one third of the pulse pressure.
Serum creatinine was assayed by a buffered kinetic Jaffe'
method (MA-kit 10, Roche, Basle, Switzerland) [131, and
plasma Na and K were measured by conventional flame
photometry. Blood glucose (Reflotest-glucose', Boehringer,
Mannheim, FRG) and hemoglobin A1 (DIAMAT Analyzer,
BlO-RAD, California, USA) [14] were determined. Normal
range for hemoglobin A1 was 4.1 to 6.1%, and interassay
coefficient of variation was 2%. Serum cholesterol was ana-
lyzed by a fully enzymatic method (CHOD-PAP, Boehringer)
[15]. The glucagon/C-peptide test was carried out after an
overnight fast. Blood samples for plasma C-peptide determina-
tion were obtained before and six minutes after an intravenous
bolus injection of 1 rng glucagon (Novo, Bagsvaerd, Denmark)
as described previously [16]. Urinary albumin concentration
was measured by radioimmunoassay (interassay coefficient of
variation was 9%) [17]. Glomerular filtration rate was measured
in all patients suffering from diabetic nephropathy, using a
single intravenous injection of 100 pCi 51Cr-EDTA at 9 a.m.,
and plasma radioactivity in venous blood samples taken 180,
200, 220, and 240 minutes after the injection were determined
[18]. Ophthalmoscopy through dilated pupils was carried out in
all patients. Body mass index [weight (kg)/height (rn)2] was
calculated.
In all the patients the maximal Na/Li countertransport
activity in the erythrocytes was measured as described in detail
previously [19, 20]. The method is summarized below.
Blood sampling and preparation of cells
Fifteen milliliters of venous blood was washed four times
within one hour after sampling and stored at 4°C in an isotonic
KCI medium containing 0.1 mM ouabain. The analysis was
performed at least within three days after sampling. Storage of
the samples for even seven days did not affect the Na/Li
countertransport. Loading of the cells with lithium was done by
washing the cells into an isotonic LiHCO3 medium (three times)
and incubating the cells in this medium for 20 minutes at 38°C at
a hematocrit of 25%.
After loading, the cells were washed five times at 4°C in large
volumes of the KCI medium in order to wash out the extracel-
lular lithium and the bicarbonate, and resuspended in this
medium to a hematocrit of 50%. This protocol was adopted
after control experiments had confirmed that lithium and the
bicarbonate were completely removed. At this stage, samples
were taken for measurements of hemoglobin by the cyanmethe-
moglobin method [21], erythrocyte concentrations of sodium
and lithium by emission flame photometry (Eppendorf, GMBH,
FRG) and hematocrit.
Analysis
Each efflux experiment was carried out by adding 0.5 ml cell
suspension to the test tubes arranged in two series, one con-
taining 4.5 ml of the KCI medium in each tube, the other
containing 4.5 ml of isotonic NaC1 medium in each tube. The
first two test tubes in each series were kept at 0°C and spun at
4000 x g in three minutes immediately after addition of the cell
suspension to get the zero values. The other tubes in the two
series were kept at 38°C and the effiux was stopped by centrif-
ugation at 0°C after 30, 60, and 90 minutes of incubation,
respectively. Duplicate samples were made in both media.
Lithium in the isolated supernates was determined by emission
flame photometry.
Calculations
Under the present experimental conditions lithium efflux is
taking place both by passive diffusion and by the Na/Li
countertransport mechanism in the NaCl medium, whereas
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Table 2. Laboratory data in patients with non-insulin-dependent diabetes with and without diabetes and in healthy non-diabetic controls
Diabetics with nephropathy Diabetics without nephropathy Non-diabetics
(N = 18) (N = 17) (N = 18)
Urinary albumin excretion rate 1873 (248—8526) 10 (4—22) —
mg/24 hr
Systolic blood pressure 162 2l 132 15 133 14
mm Hg
Diastolic blood pressure 92 9 q3 7 83 7
mm Hg
Glomerular filtration rate 51(27—146) — —
mI/mm 1.73 m2
Serum creatinine 142 76 75 15 80 12
p.mol/liter
Blood glucose 10.3 (4.4—19.8) 12.6 (4.2—20.0) 4.6 (3.0—5.9)
mmol/liter
Hemoglobin A1 7.6 (5.6—12.3) 8.4 (6.2—10.1) —
%
Serum cholesterol 6.9 (4.7—13.1) 5.6 (3.9—8.6) —
mmol/liter
P-potassium 4.1 0.4 4.0 0.3 4.3 0.5
mmollliter
a P < 0.001 as compared with values in diabetics without nephropathy and in non-diabetics
b p < 0.05 as compared with values in diabetics without nephropathy
lithium effiux takes place by passive diffusion only in the KCI
medium. Hence the Na/Li countertransport activity can be
calculated by subtracting the rate of increase in lithium concen-
tration with time in the KC1 medium from the rate of increase in
lithium concentration with time in the NaCl medium. The rate
of increase in lithium concentration in the two media was
calculated by linear regression analysis of the four duplicate
lithium concentrations versus time. The correlation coefficients
were always above 0.99, indicating constant effiux rates during
the experiments (90 mm). Saturation of the countertransport
system is obtained at an intracellular lithium concentration
above 5 mmol/l cells [201. Lithium concentration was deter-
mined to be above this level (7 to 12 mmollliter cells) in all the
measurements. Intracellular sodium concentration and the
mean corpuscular hemoglobin concentration (MCHC) were
within physiological ranges. The last finding indicates that the
erythrocytes had normal cell volume and water content after
the storage and the lithium loading. We have demonstrated that
transport parameters, changed in the presence of bicarbonate,
return to normal after cells have been washed back into chloride
media. Furthermore, we have found identical values for the
leak effiux of lithium in KC1 medium and media used in other
laboratories [201. The interassay and intraindividual coefficients
of variation were 6.1 and 7.1%, respectively. The laboratory
was blinded with respect to which group the blood samples
belonged to. All chemicals employed were reagent grade.
Statistical analysis
Values are expressed as mean SD. For skewed data values
are expressed as median with range. In order to test for
differences between the three groups, the Kruskall-Wallis test
of variance was used. The Mann-Whitney test was used when
comparisons were made between two groups. Correlations
were sought by using Spearmen rank correlations. A P value
(two-tailed) <0.05 was considered statistically significant.
Results
The clinical and laboratory data in the diabetic and non-
diabetic groups are shown in Tables 1 and 2. Since all the
non-insulin-dependent diabetic patients were men, we included
men only in the two other groups. The two diabetic groups were
well matched with respect to age, known duration of diabetes,
antidiabetic treatment, blood glucose concentration, hemoglo-
bin A1, and obesity. It should be noticed that 6 out of the 18
patients with nephropathy lacked retinopathy. Serum-choles-
terol was elevated in patients with nephropathy compared to
patients without this disease, 6.9 (range 4.7 to 13.1) versus 5.6
(3.9 to 8.6) mmollliter, respectively (P < 0.05). Serum K was
about the same in all three groups.
The maximal Na/Li countertransport was identical in
patients with and without nephropathy: 0.43 (0.24 to 0.92)
versus 0.44 (0.20 to 0.83) mmol/(liter cells x hr; Fig 1).
Compared to Na/Li countertransport in non-diabetics (0.32,
range 0.09 to 0.73), countertransport was elevated in the
diabetics (P < 0.05), but not when data were analyzed sepa-
rately for each of the two groups: diabetics with nephropathy (P
= 0.09) and without nephropathy (P = 0.05). Within each group
there were no statistically significant correlations between the
rate of Na/Li countertransport in the red cells and any of the
measured variables. The possible interaction between the de-
gree of glycemic control (hemoglobin A1) and the maximal
velocity of Na/Li countertransport was also analyzed in the
whole diabetic group. Patients with (N = 18) a Na/Li
countertransport in excess of the median value [0.44 mmoll(liter
cells x hr)1 had a hemoglobin A1 of 8.5 (6.0 to 12.3) % as
compared to 8.0 (5.6 to 9.5) % in patients with (N = 17) a
Na/Li countertransport below the median.
Discussion
Our cross sectional study has demonstrated that the Na/Li
countertransport in the red cells is about the same in non-
insulin-dependent diabetic patients with and without diabetic
nephropathy. Furthermore, we have demonstrated enhanced
red cell Na/Li countertransport in non-insulin-dependent
diabetic patients as compared to non-diabetic healthy subjects.
Our normal values for maximal velocity of Na4iLi counter-
transport in the red cells are comparable with those previously
reported in male subjects [9, 22—271. The lack of difference
between the diabetic patients with and without persistent albu-
minuria cannot be explained by heterogeneity with respect to
etiology of albuminuria. All our albuminuric patients were
suffering from diabetic glomerulosclerosis with no other lesions
(biopsy proven). This inclusion criterion is crucial, since non-
diabetic glomerulopathies are more frequent causes of albumin-
uria in non-insulin-dependent as compared to insulin-dependent
diabetic patients [28]. Non-insulin-dependent diabetic patients
with normal urinary albumin excretion rate have a cumulative
risk of developing clinical albuminuria of apprOximately 5%
during a nine year follow-up period, while patients with mi-
croalbuminuria have a fourfold higher risk [29]. All our patients
without nephropathy had normal urinary albumin excretion
rate.
A number of environmental factors have been reported to
influence the red cell Na/Li countertransport in humans.
Enhanced activity can be induced by hypokalemia [30], hyper-
lipidemia [311, obesity [25], and use of oral contraceptives [301,
while exercise can reduce the activity [32]. Serum K concen-
tration was normal and about the same in all three groups, while
elevated serum cholesterol was present in the patients with
diabetic nephropathy. Body mass index was about the same in
all groups (P > 0.05). We only investigated males and none of
the albuminuric patients received hemodialysis. Since race may
influence the red cell Na/Li countertransport [33, 34], it
should be mentioned that only Caucasians were studied by us.
Dietary manipulations, such as changes in caloric and salt
intake, do not affect red blood cell Na/Li countertransport,
as reviewed by Canessa, Brugnara and Escobales [35]. Recent
studies have demonstrated that insulin in physiological concen-
trations can reduce red cell Na/Li countertransport in vitro
[361. The non-insulin-dependent diabetic state is usually char-
acterized by hyperinsulinemia and peripheral insulin resistance,
particularly in obese patients. Even though we did not measure
plasma insulin concentrations, it seems fair to assume that our
obese diabetic patients had hyperinsulinemia. This would tend
to suppress Na/Li countertransport if the reported in vitro
phenomenon is also present in vivo. Mangili et al [9] found no
correlation between free plasma insulin concentrations and red
blood cell Na/Li countertransport. Finally, antihypertensive
medication with diuretics, beta-blockers and angiotensin I
converting enzyme inhibitors has no demonstrable effect on red
cell Na/Li countertransport [30, 37]. If potassium deficit was
induced by antihypertensive treatment with a diuretic, en-
hanced countertransport activity was observed [301.
In several investigations Na/Li countertransport in red
cells is elevated in a majority of patients with essential hyper-
tension [38, 391. Increased Na/Li countertransport has been
suggested as a genetic marker for essential hypertension in
non-diabetic subjects [40, 41]. Trevisan et a! [26] found normal
values of red cell Na/Li countertransport in normoprotein-
uric non-insulin-dependent diabetic patients with and without
hypertension. However, in a recent large population-based
study, the same group [421 reported elevated Na/Li counter-
transport in 98 diabetics independent of anti-diabetic therapy.
In this study there were no differences in countertransport
activity between the hypertensive and the normotensive diabet-
ics. Information regarding this marker in insulin-dependent
diabetic patients with essential hypertension is still lacking.
Originally, Krolewski et al [8] and Mangili et al [9] reported
elevated Na/Li1 countertransport in red cells in insulin-
dependent with incipient and overt diabetic nephropathy. This
finding has been confirmed [43, 44] and also extended to include
insulin-dependent diabetic patients without nephropathy, sug-
gesting an effect of the diabetic state per se [43, 44]. Our study
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in non-insulin-dependent diabetic patients supports this sugges-
tion of an effect of diabetes on red cell Na/Li countertrans-
port. However, it should be stressed that the elevated Na/Li
countertransport was not explained by poorer glycemic control,
since the median glycosylated hemoglobin A1 values were
similar in our non-insulin-dependent diabetic patients with
elevated or normal Na/Li countertransport. Furthermore, no
correlation was found between hemoglobin A1ç, and the Na/
Li countertransport in the present or the previous studies
dealing with insulin-dependent diabetic patients [8, 9, 45};
however in the population-based study by Trevisan et al [421
Na/Li countertransport correlated with plasma glucose. The
mechanisms involved remain to be clarified.
In conclusion, our cross sectional study does not support the
concept that predisposition to hypertension, as indicated by
elevated red cell Na/Li countertransport, may serve as a
marker for the risk of diabetic nephropathy in non-insulin-
dependent diabetic patients.
Reprint requests to Man-Anne Gall, M.D., Hvidôre Hospital, Emi-
liekildevef 1, DK-2930 Klampenborg, Denmark.
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